The results of these trials are corroborated by studies of the potential effects of SGLT2 inhibitors on pathways linking diabetes to heart failure, including insulin resistance, myocardial fat accumulation, cardiac function, cardiac metabolism, as well as arterial stiffness [9, 10]. The gene discussed is SLC5A2; the disease is heart failure.